Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Panagiotis A. Konstantinopoulos, D. Gulhan et al.|Nature Communications|2020Cited by 342
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpressionParomita Raha, Pamela N. Münster|Breast Cancer Research|2015Cited by 95
Efficacy of Histone Deacetylase and Estrogen Receptor Inhibition in Breast Cancer Cells Due to Concerted down Regulation of AktScott Thomas, Pamela N. Münster|PLoS ONE|2013Cited by 30
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Panagiotis A. Konstantinopoulos, D. Gulhan et al.|Nature Communications|2020Cited by 13
Abstract 4487: Association of the tumor-immune microenvironment with response to niraparib and pembrolizumab in relapsed, platinum-resistant ovarian cancerAnniina Färkkilä, Panagiotis A. Konstantinopoulos, Jia‐Ren Lin et al.|Immunology|2019Cited by 0